Get startedLog in
    Picture of Novo Nordisk A/S logo

    NVO — Novo Nordisk A/S News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapSuper Stock
    All News

    Brief: Novo: CagriSema Shows Greater Weight Loss Than Tirzepatide In Trial

    Picture of Novo Nordisk A/S logoNovo Nordisk A/S
    21/09/2026 11:31
    BRIEF-Novo: CagriSema Shows Greater Weight Loss Than Tirzepatide In Trial
    Sept 21 (Reuters) - Novo Nordisk A/S NOVOb.CO:
    • NOVO'S CAGRISEMA DELIVERS SUPERIOR WEIGHT LOSS VERSUS TIRZEPATIDE IN REIMAGINE 5 TRIAL
    • CAGRISEMA 1.0 MG/1.0 MG ACHIEVES 12.4% WEIGHT LOSS VERSUS 9.1% TIRZEPATIDE AT WEEK 60
    • CAGRISEMA 1.0 MG/1.0 MG CONFIRMS NON-INFERIOR HBA(1C) REDUCTION OF 1.71% VERSUS 1.67% TIRZEPATIDE
    • CAGRISEMA SHOWS GREATER IMPROVEMENTS THAN PLACEBO IN MULTIPLE SUPPORTIVE ENDPOINTS
    • IN REDEFINE 9, CAGRISEMA 1.0 MG/1.0 MG PROVIDED A WEIGHT REDUCTION OF 21.0% VERSUS 2.0% FOR PLACEBO, AND PRIMARY SUPERIORITY ENDPOINT WAS MET
    Source text: ID:nGNE3v7z6Y
    Further company coverage: [NOVOb.CO]

     (Gdansk Newsroom)
     ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

    Recent news on Novo Nordisk A/S

    See all news